| 9.02 0.14 (1.58%) | 09-04 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index. A minimum of 80% of the fund's overall holdings will consistently be directed towards these specific index components. Notably, this fund operates as a non-diversified investment vehicle.
Fri, 19 Jul 2024
Investing in Nobel Prize Achievements – Immunology To Treat Cancer - Securities.io
Wed, 22 Mar 2023
Healthcare Stocks List: Top Healthcare Companies & ETFs - Bullish Bears
Wed, 15 Mar 2023
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector - InvestorPlace
Tue, 14 Jul 2020
Moderna Study Sends Biotech ETFs And Stock Futures Surging - ETF Trends
Sun, 08 Apr 2018
Cancer-Focused ETF Tops the Charts - WSJ
Sat, 25 Mar 2017
How to Choose an ETF - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |